<DOC>
	<DOCNO>NCT00958906</DOCNO>
	<brief_summary>The purpose study determine intravitreal infliximab safe effective treatment macular edema secondary uveitis .</brief_summary>
	<brief_title>Pilot Study Evaluation Intravitreal Infliximab Treatment Uveitic Macular Edema</brief_title>
	<detailed_description>Participants uveitic macular edema treat one injection intravitreal infliximab ( 2.0mg/0.05ml ) follow three month . Outcomes assessed include best-corrected visual acuity , macular thickness measure optical coherence tomography , electroretinogram response .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1 . Participant must 18 year age old . 2 . Participant must understand sign protocol 's informed consent document . 3 . Participants must uveitic macular edema one eye define follow criterion : 1 . Presence active intermediate uveitis posterior uveitis . 2 . Macular edema define central macular thickness ≥ 250 μm OCT. 3 . Uveitis must noninfectious determined standard investigation use diagnostic investigation uveitis . 4 . Participant must visual acuity 20/40 hand motion study eye . 5 . Participant must steady fixation study eye medium clear enough good quality imaging . 6 . Female participant childbearing potential must pregnant breastfeeding , must negative pregnancy test screening must practice adequate method birth control . Males able father child must agree practice birth control . Acceptable method birth control include hormonal contraception ( birth control pill , inject hormone vaginal ring ) , intrauterine device , barrier method spermicide ( diaphragm spermicide , condom spermicide ) surgical sterilization ( hysterectomy , tubal ligation vasectomy partner ) . If participant childbearing potential , must willing undergo monthly urine pregnancy test . Both male female must agree use adequate birth control three month intravitreal infliximab injection . 1 . Participant another investigational study actively receive study therapy . 2 . Participant unable comply study procedure followup visit . 3 . Participant uveitic macular edema ( define ) eye . 4 . Participant multiple sclerosis symptom suggestive multiple sclerosis . 5 . Participant evidence ocular disease uveitis either eye may confound outcome study ( e.g. , diabetic retinopathy , agerelated macular degeneration , vitreomacular traction , moderate/severe myopia , etc. ) . 6 . Participant expect need ocular surgery study eye course study . 7 . Participant undergone ocular surgery intravitreal/periocular steroid injection study eye within past 3 month . 8 . Participant YAG laser capsulotomy intravitreal antiVEGF treatment study eye within past 6 week . 9 . Participant par plana vitrectomy study eye . 10 . Participant ocular systemic medication know toxic lens , retina , optic nerve . 11 . Participant history ocular herpes simplex virus infection study eye . 12 . A condition , opinion investigator , would preclude participation study ( e.g. , unstable medical status include blood pressure glycemic control ) . 13 . There criteria inclusion/exclusion fellow eye . Only one eye macular edema order potential participant consider enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Infliximab</keyword>
	<keyword>Uveitis</keyword>
	<keyword>Macular Edema</keyword>
	<keyword>Intraocular Inflammation</keyword>
</DOC>